My experiences with Bayesian methods and complex innovative designs as a regulator

Presenters: James Travis, CDER, FDA

Increasingly there are more and more proposals for trials utilizing Bayesian designs both within the complex innovative trial design program and more generally submitted to the Center for Drug Evaluation and Research at the US FDA. In this presentation I will discuss my experience as a regulator with Bayesian designs and the key challenges that had to be overcome to successfully implement these designs.

Disclaimer: This speech reflects the views of the author and should not be construed to represent FDA's views or policies.